Kennedy has been criticized for making false medical claims, including that vaccines are linked to autism. He also suggested he would gut the 18,000-employee Food and Drug Administration and ...

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations.

Along with NASH, Novo Nordisk is also planning to investigate the drug's activity in chronic kidney disease and cardiometabolic conditions. She added that VENT-01 has the potential to offer "best ...

Novo Nordisk A/S (NVO)’s share was trading at $109.09 as of Nov 11th. NVO’s trailing and forward P/E were 35.82 and 27.70 respectively according to Yahoo Finance. Novo […] ...

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:NVO). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Novo Nordisk also announced plans to establish a new $800 million production facility in Denmark for tableting and packaging of oral products. That investment will create an estimated 100 new jobs.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

LONDON (Reuters) -Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes ...

Novo's new obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.